Bioverativ Inc.

Read more
John G Cox's photo - CEO of Bioverativ Inc.

CEO

John G Cox

CEO Approval Rating

64/100

Founded:

2016

Status:

PrivateSubsidiary of Sanofi S.A

Est. Annual Revenue
$1.2B
Agree?
Est. Employees
350
Agree?

BIOVERATIV INC. TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Bioverativ Inc.'s company profile
John G Cox's photo - CEO of Bioverativ Inc.

John G Cox

CEO

64/100
350
$0
$1.2B
View Profile
1
Bioverativ Inc.'s Competitor - Baxter logo
Jose E Almeida's photo - Chairman & CEO of Baxter

Jose E Almeida

Chairman & CEO

64/100
50,000
$1.8M
$12.2B
View Profile
2
Bioverativ Inc.'s Competitor - Grifols logo
Raimon Grifols Roura's photo - Co-CEO of Grifols

Raimon Grifols Roura

Co-CEO

85/100
24,016
- -
$6.5B
View Profile
3
Bioverativ Inc.'s Competitor - Fresenius logo
Stephan Sturm's photo - Chairman & CEO of Fresenius

Stephan Sturm

Chairman & CEO

87/100
310,842
- -
$45B
View Profile
4
Bioverativ Inc.'s Competitor - Roche logo
Severin Schwan's photo - CEO of Roche

Severin Schwan

CEO

89/100
100,000
$7.8B
$68.3B
View Profile
5
Bioverativ Inc.'s Competitor - Sanofi Pasteur logo
Olivier Brandicourt's photo - CEO of Sanofi Pasteur

Olivier Brandicourt

CEO

68/100
16,002
- -
$5.1B
View Profile
6
Bioverativ Inc.'s Competitor - Johnson & Johnson logo
Alex Gorsky's photo - Chairman & CEO of Johnson & Johnson

Alex Gorsky

Chairman & CEO

82/100
135,100
- -
$89.2B
View Profile
7
Bioverativ Inc.'s Competitor - Abbott logo
Robert B. Ford's photo - President & CEO of Abbott

Robert B. Ford

President & CEO

69/100
103,000
$6.9M
$40.2B
View Profile
8
Bioverativ Inc.'s Competitor - Medtronic logo
Geoffrey S. Martha's photo - Chairman & CEO of Medtronic

Geoffrey S. Martha

Chairman & CEO

95/100
86,000
- -
$31.6B
View Profile
9
Bioverativ Inc.'s Competitor - Boston Scientific logo
Michael F. Mahoney's photo - Chairman & CEO of Boston Scientific

Michael F. Mahoney

Chairman & CEO

66/100
32,000
$2.1B
$11.2B
View Profile
10
Bioverativ Inc.'s Competitor - Octapharma logo
Wolfgang Marguerre's photo - Chairman & CEO of Octapharma

Wolfgang Marguerre

Chairman & CEO

70/100
9,067
- -
$2.9B
View Profile
11
Bioverativ Inc.'s Competitor - CSL  logo
Paul Perreault's photo - CEO of CSL

Paul Perreault

CEO

78/100
25,415
$750M
$10.3B
View Profile
12
Bioverativ Inc.'s Competitor - Novartis logo
Vasant Narasimhan's photo - CEO of Novartis

Vasant Narasimhan

CEO

87/100
110,000
- -
$50.4B
View Profile

Missing a competitor? Contribute!

Baxter is Bioverativ Inc.'s #1 rival. Baxter was founded in 1931 in Deerfield, Illinois. Baxter is in the Health Care Equipment field. Baxter generates $11B more revenue than Bioverativ Inc..

Grifols is one of Bioverativ Inc.'s top competitors. Grifols is headquartered in Barcelona, Barcelona, and was founded in 1909. Grifols competes in the Health Care Equipment field. Grifols generates 557% the revenue of Bioverativ Inc..

Fresenius is seen as one of Bioverativ Inc.'s top competitors. Fresenius was founded in 1912, and its headquarters is in Bad Homburg, Hesse. Like Bioverativ Inc., Fresenius also operates in the Health Care Services space. Fresenius has 310,492 more employees than Bioverativ Inc..

Bioverativ Inc. Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
True North Therapeutics, Inc.

May 2017

Source »
$400M
True North is a biotechnology company that engages in research and development of humanized antibodies and novel therapies to treat rare diseases.

These are all the companies that Bioverativ Inc. has acquired. Bioverativ Inc.'s latest acquisition was True North Therapeutics, Inc. in May 2017. True North is a biotechnology company that engages in research and development of humanized antibodies and novel therapies to treat rare diseases.

Bioverativ Inc. Funding History

No recent funding data found related to Bioverativ Inc.

Bioverativ Inc. Investments

No recent investments found related to Bioverativ Inc.

Bioverativ Inc. News

December 2, 2018PharmiWeb

At ASH, Extended Half-life Therapies Elocta® and Alprolix® Demonstrate Proven Efficacy and Well-characterised Safety Over Four Years

At ASH, Extended Half-life Therapies Elocta® and Alprolix® Demonstrate Proven Efficacy and Well-chara... See more »
November 19, 2018Pharamceutical Technology

SOBI bets on the haemophilia market

In 2006, Swedish Orphan Biovitrum (SOBI) partnered with Bioverativ to develop a new generation of hae... See more »
November 12, 2018BioPortfolio

Bioverativ Inc BIVV Medical Equipment Deals and Alliances Profile Report Updated 16102018 Prices from USD $250

SummaryBioverativ Inc Bioverativ is a biotechnology company that discovers develops and markets thera... See more »
August 31, 2018BioPortfolio

Bioverativ Inc BIVV Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 16042018 Prices from USD $250

SummaryBioverativ Inc Bioverativ is a biotechnology company that discovers develops and markets thera... See more »
August 15, 2018PMLiVE

Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon

US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader.... See more »
May 21, 2018FierceBiotech

Bioverativ says data back twice-a-month dosing for hemophilia A drug

Sanofi is trumpeting new clinical data for a hemophilia A drug developed by Bioverativ that it conten... See more »
May 21, 2018FinanzNachrichten

Bioverativ Presents Preliminary Phase 1/2a Data on BIVV001, the First Factor VIII Therapy to Break Through the VWF Half-Life Ceiling in Hemophilia A

BIVV001 demonstrates unprecedented half-life of 37 hours with high factor VIII activity of 5.6% at se... See more »

Bioverativ Inc. Press Releases

January 24, 2018Business Wire

The Law Offices of Vincent Wong Notifies Investors of an Investigation of Bioverativ Inc. in Connection with the Sale of the Company to Sanofi

NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong are investigating the Board of Directors o... See more »
December 9, 2017StreetInsider

ALPROLIX® Demonstrates Higher Tissue Distribution and Retention in Joints Compared to Other Factor IX Molecules in a Preclinical Imaging Study

Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the live... See more »
August 2, 2017StreetInsider

Bioverativ Reports Second Quarter 2017 Performance

Bioverativ Inc. (NASDAQ: BIVV) today reported financial results for the second quarter of 2017.... See more »

Bioverativ Inc. Videos

Social Media

Bioverativ Inc. Headquarters

225 2nd Ave

Waltham, Massachusetts02451

Driving Directions »

Trending Companies

Bioverativ Inc. Summary

ABOUT

Overview

Bioverativ develops and commercializes drug therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. was founded in 2016. Bioverativ Inc.'s headquarters is located in Waltham, Massachusetts, USA 02451. Bioverativ Inc.'s lat...

CEO

Bioverativ Inc.'s CEO, John G Cox, currently has an approval rating of 64%. Bioverativ Inc.'s primary competitors are Baxter, Grifols & Fresenius.

Frequently Asked Questions about Bioverativ Inc.

  1. When was Bioverativ Inc. founded?

    Bioverativ Inc. was founded in 2016
  2. Who is Bioverativ Inc.'s CEO?

    Bioverativ Inc.'s CEO is John G Cox
  3. How much revenue does Bioverativ Inc. generate?

    Bioverativ Inc. generates $1.2B in revenue
  4. How much funding does Bioverativ Inc. have?

    Bioverativ Inc. has historically raised $0 in funding
  1. Where is Bioverativ Inc.'s headquarters?

    Bioverativ Inc.'s headquarters is in Waltham Massachusetts, USA
  2. How many employees does Bioverativ Inc. have?

    Bioverativ Inc. has 350 employees
  3. What sector does Bioverativ Inc. operate in?

    Bioverativ Inc. is in Health Care Services
  4. Who are Bioverativ Inc.'s competitors?

    Bioverativ Inc.'s top competitors are Baxter, Grifols, Fresenius